Conjugate Or Complex Of Monoclonal Or Polyclonal Antibody, Immunoglobulin, Or Fragment Thereof With Nonimmunoglobulin Material Patents (Class 424/178.1)
  • Patent number: 11369658
    Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: June 28, 2022
    Assignee: SEAGEN INC.
    Inventors: Eric Sievers, Dana Kennedy
  • Patent number: 11370838
    Abstract: The invention provides improved methods of conjugating an agent to a thiol moiety in a protein that contains at least one disulfide bond and at least one trisulfide bond. Exemplary embodiments include the production of antibody drug conjugates substantially free of impurities created in the presence of reactive sulfide moieties in the production processes.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: June 28, 2022
    Assignee: GENENTECH, INC.
    Inventors: Jayme Franklin, Xin Xin Lin, Jeffrey Gorrell, Timothy Tully, Matthew Hutchinson, Charity Tucker Bechtel
  • Patent number: 11364297
    Abstract: The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2. The cell is also contacted with one or more therapeutic agents (such as an anti-cancer agent), for example about 0 to 8 hours after irradiating the cell, thereby killing the cell. Also provided are methods of imaging cell killing in real time, using fluorescence lifetime imaging. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: June 21, 2022
    Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Hisataka Kobayashi, Peter Choyke
  • Patent number: 11365240
    Abstract: The present invention relates to novel antibodies that are specific for human serum albumin (HSA).
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: June 21, 2022
    Assignee: Numab Therapeutics AG
    Inventors: Tea Gunde, Sebastian Meyer, Christian Hess, Tessa Bieri
  • Patent number: 11364298
    Abstract: The present disclosure relates to compositions and methods of killing cells in vitro or in vivo. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein. In particular examples the antibody recognizes a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2, thereby killing the cell. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: June 21, 2022
    Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Hisataka Kobayashi, Peter Choyke
  • Patent number: 11352404
    Abstract: Fusion molecules of a cytokine or portion thereof and a polypeptide which targets the fusion protein to phosphatidylserine, pharmaceutical compositions thereof, and methods for their use in targeting a cytokine or portion thereof to a pathological site and treating a disease or condition responsive to cytokine treatment are provided.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: June 7, 2022
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Sergei V. Kotenko, Raymond B. Birge, Viralkumar Rameshkumar Davra
  • Patent number: 11351257
    Abstract: This invention relates to stable formulations that can be prepared to high concentration of active agent using low amounts of detergents and to methods for producing such formulations. In particular, this invention relates to formulations containing the L19-TNF? immunocytokine.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: June 7, 2022
    Assignee: PHILOGEN S.P.A.
    Inventors: Giovanni Neri, Camilla Bacci
  • Patent number: 11339197
    Abstract: A modified EGF protein, a production method therefor, and a use thereof are disclosed. The modified EGF protein allows an effective delivery of EGF into the cell and exhibits an enhanced half-life span. A method for producing the modified EGF protein includes culturing conditions where host cell growth phase and protein expression phase employ different temperature conditions. A use of the modified EGF protein is also disclosed.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: May 24, 2022
    Assignee: PROGEN CO., LTD.
    Inventors: Zungyoon Yang, Eun Joo Nam
  • Patent number: 11331378
    Abstract: The present disclosure provides methods for prophylactically treating a subject for viral infections comprising topically administering a ranpirnase composition. The disclosure also provides compositions that could be used for prophylactic treatment.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: May 17, 2022
    Assignee: ORGENESIS INC.
    Inventors: Luis Squiquera, Thomas Hodge, Jamie Sulley
  • Patent number: 11319344
    Abstract: The present invention relates to non-membrane disruptive and p53 activating stapled peptides, as well as methods of treatment of cancer involving the use of these peptides. In one embodiment, the peptide comprises or consist of the amino acid sequence of TSFXaa1EY-WXaa3LLXaa2, where Xaa1 is (R)-2-(7?-octenyl)alanine or derivative thereof, or is (R)-2-(4?-pentenyl)alanine or derivative thereof; and Xaa2 and Xaa3 are independently any type of amino acid or modified amino acid. In another embodiment, the peptide comprising or consisting of the amino acid sequence of TSFXaa1EYW Xaa3LLXaa2ENXaa5, wherein Xaa1 and Xaa3 are any type of amino acid or modified amino acid; Xaa2 is S, or P, or (S)-2-(4?-pentenyl)alanine or a derivative of (S)-2-(4?-pentenyl)alanine; and wherein Xaa5 is F or Y.
    Type: Grant
    Filed: February 15, 2016
    Date of Patent: May 3, 2022
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: Yaw Sing Tan, Christopher John Brown, Chandra S. Verma, Fernando Jose Ferrer Gago, David P. Lane, Thomas Joseph
  • Patent number: 11318103
    Abstract: Methods for inhibiting tissue ossification or calcification in a subject, comprising administering a therapeutically effective amount of BMP I inhibitor-loaded microparticles to a subject in need thereof, wherein the administration provides local and sustained release of the BMP I inhibitor thereby inhibiting tissue ossification or calcification.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: May 3, 2022
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, Ri.Med Foundation
    Inventors: Riccardo Gottardi, Peter Alexander, Patrick A. Bianconi, Steven R. Little
  • Patent number: 11292825
    Abstract: The invention relates to protein conjugates and in particular conjugates of more than two protein or polypeptides. The compounds include a trivalent linker moiety that enables efficient production of desired products.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: April 5, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Emiliano Clo, Mikael Kofod-Hansen, Henrik Sune Ramirez-Andersen, Nils Langeland Johansen
  • Patent number: 11286528
    Abstract: The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: March 29, 2022
    Assignees: BIOVERATIV THERAPEUTICS INC., PUGET SOUND BLOOD CENTER
    Inventors: Haiyan Jiang, Tongyao Liu, Sriram Krishnamoorthy, Neil Josephson, Glenn Pierce
  • Patent number: 11267723
    Abstract: A method of purifying a plurality of metal oxide particles produced from a synthesis process comprising the step of washing a plurality of metal oxide particles in a first solvent composition comprising of at least one aliphatic ether, and at least one flocculant. In one embodiment, the plurality of metal oxide particles are iron oxide particles produced from a thermal decomposition synthesis process between an iron-oleate complex and oleic acid in 1-octadecene, wherein the first solvent composition comprises a 1:1 (vol/vol) ratio of an aliphatic ether in the form of diethyl ether and a flocculant in the form of methanol. The washed iron oxide particles are further washed in a second solvent composition comprising a 1:1 (vol/vol) ratio of hexane and ethanol, and then finally dispersed in hexane. The resulting iron oxide particles find use as a contrast agent for magnetic resonance imaging (MRI) or as magnetic particles in magnetic separation, magnetism-directed targeting or magnetism-induced heating.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: March 8, 2022
    Assignee: Royal Melbourne Institute of Technology
    Inventors: Amanda Anderson, Vipul Bansal, Jos Laurie Campbell, Rajesh Ramanathan, Jyoti Arora, Ravi Shukla
  • Patent number: 11248049
    Abstract: This application provides isolated antibodies, and antigen-binding fragments thereof, that specifically bind Programmed Death 1 (PD-1). These PD-1 antibodies, or antigen-binding fragments thereof, have a high affinity for PD-1, function to inhibit PD-1, are less immunogenic compared to their unmodified parent antibodies in a given species (e.g., a human), are capable of increasing T-cell proliferation and IL-2 secretion in a mixed lymphocyte reaction, and can be used to treat human diseases (e.g., cancer, infectious diseases, autoimmune diseases, asthma, transplant rejection, and inflammatory disorders).
    Type: Grant
    Filed: December 23, 2017
    Date of Patent: February 15, 2022
    Assignee: REMD Biotherapeutics, Inc.
    Inventors: Frank J Calzone, Hai Yan, John Zhang
  • Patent number: 11242403
    Abstract: Presented herein, in certain embodiments, are compositions comprising binding agents that specifically bind to syndecan-1 and uses thereof.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: February 8, 2022
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Julia Coronella, Robyn Richardson, Anjuli Timmer, Roland Newman
  • Patent number: 11230589
    Abstract: Novel fusion molecules and uses are disclosed.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: January 25, 2022
    Assignee: FOUNDATION MEDICINE, INC.
    Inventors: Doron Lipson, Roman Yelensky, Joel Robert Greenbowe, Jie He
  • Patent number: 11224663
    Abstract: Drug conjugates of formula [D-(X)b-(AA)w-(L)-]n-Ab wherein: D is a drug moiety having the following formula (I) or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, wherein: A is selected from (II) and (III) R1, R2 and R3 is H, ORa, OCORa, OCO—ORa, alkyl, alkenyl, alkynyl, etc.; R3? is, CORa, COORa, CONRaRb, etc; each of R4 to R10 and R12 is alkyl, alkenyl or alkynyl; R11 is H, CORa, COORa, alkyl, alkenyl or alkynyl, or R11 and R12+N+C atoms to which they are attached may form a heterocyclic group; each of R13 and R14 is H, CORa, COORa, alkyl, alkenyl or alkynyl; each Ra and Rb is H, alkyl, alkenyl, alkynyl, etc.
    Type: Grant
    Filed: June 2, 2014
    Date of Patent: January 18, 2022
    Assignee: PHARMA MAR, S.A.
    Inventors: Cármen Cuevas Marchante, Juan Manuel Domínguez Correa, Andrés Francesch Solloso, María Garranzo García-Ibarrola, María José Munoz Alonso, Francisco Sánchez Madrid, Juan Manuel Zapata Hernández, Alicia García Arroyo, Maria Ángeles Ursa Pecharromán
  • Patent number: 11191815
    Abstract: A closed-loop insulin delivery system is described. More particularly, the presently disclosed insulin delivery system can comprise glucose-responsive vesicles that release insulin in response to hypoxia triggered by enzymatic reduction of glucose. In addition or as an alternative to insulin, the delivery system can release other diabetes treatment agents, such as non-insulin-based diabetes treatment agents. The vesicles can be prepared from a hypoxia sensitive polymer, such as a hypoxia-sensitive hyaluronic acid (HS-HA). The HS-HA can comprise hydrophobic groups that can be reduced in hypoxic environments to form hydrophilic groups. The vesicles can be loaded into microneedles and microneedle array patches for use in the treatment of diabetes or to otherwise regulate blood glucose levels in subjects in need of such treatment.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: December 7, 2021
    Assignee: North Carolina State University
    Inventors: Zhen Gu, Jicheng Yu
  • Patent number: 11192954
    Abstract: The present invention generally relates to compounds comprising antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to TROP2 (TACSTD2). The present invention also relates to methods of using such TROP2-binding molecules for diagnosing and treating diseases, such as malignancies.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: December 7, 2021
    Assignee: Bio-Thera Solutions, Ltd.
    Inventors: Weijia Tang, Xiaoyang Huang, Jin-Chen Yu, Ziqiang Ou, Xian Peng, Yili Yang, Shengfeng Li, Chao Qin
  • Patent number: 11173214
    Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: November 16, 2021
    Assignee: LegoChem Biosciences, Inc.
    Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung Soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee
  • Patent number: 11168306
    Abstract: Disclosed herein, inter alia, are compositions and methods useful for improving detection of analytes. The compositions and methods provided include polymer-wrapped viral particles useful, inter alia, for the detection of PSMA.
    Type: Grant
    Filed: February 25, 2015
    Date of Patent: November 9, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Gregory A. Weiss, Kritika Mohan, Lindsay Kindra, Reginald M. Penner
  • Patent number: 11168146
    Abstract: Novel antibodies, such as single domain antibodies (sdAbs), or fragments thereof that specifically bind a transferrin are described. Compositions, methods and systems for increasing the half-life of a target protein in a serum using an antibody or fragment thereof against a transferrin are described.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: November 9, 2021
    Assignee: Nanjing Legend Biotech Co., Ltd.
    Inventors: Fang Liang Zhang, Jianbing Zhang, Shu Wu
  • Patent number: 11162085
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Grant
    Filed: March 3, 2020
    Date of Patent: November 2, 2021
    Assignee: ACCELERON PHARMA INC.
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • Patent number: 11147857
    Abstract: A modified IgG4 Fc fragment useful as a drug carrier is disclosed. When coupled to a drug, the resulting drug-IgG4 Fc conjugate can minimize the effector functions of the IgG4 Fc and the chain exchange with in vivo IgG while maintaining in vivo activity and improving in vivo duration of the drug conjugate.
    Type: Grant
    Filed: November 13, 2020
    Date of Patent: October 19, 2021
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Sung Youb Jung, Yong Ho Huh, Sung Hee Park, Jong Soo Lee, In Young Choi
  • Patent number: 11135304
    Abstract: Provided herein are conjugated immunoglobulins and methods for generating conjugated immunoglobulins using a microbial transglutaminase.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: October 5, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Jared Spidel, Earl Albone
  • Patent number: 11135275
    Abstract: Described are procoagulant proteins which may, for example, be fusion proteins or chemical conjugates; methods of producing procoagulant proteins; polynucleotides that encode fusion proteins and cells that expresses them. Furthermore, described are procoagulant proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with such procoagulant proteins.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: October 5, 2021
    Assignee: Novo Nordisk Healthcare AG
    Inventors: Ida Hilden, Bernd Peschke, Jens Breinholt, Mikael Kofod-Hansen
  • Patent number: 11130730
    Abstract: The invention relates to novel compounds with the ability to link an immune response to a defined therapeutic target, to the use of said compounds in treating cancer and infectious diseases, to compositions containing said compounds, processes for their preparation and to novel intermediates used in said process.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: September 28, 2021
    Assignee: CENTAURI THERAPEUTICS LIMITED (GB/GB)
    Inventors: Melanie Glossop, Christine Watson
  • Patent number: 11123439
    Abstract: The present invention relates to novel binder-prodrug conjugates (APDCs) where binders are conjugated with inactive precursor compounds of kinesin spindle protein inhibitors, and to antibody-drug conjugates ADCs and to processes for producing these APDCs and ADCs.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: September 21, 2021
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hans-Georg Lerchen, Anne-Sophie Rebstock, Yolanda Cancho Grande, Leo Marx, Beatrix Stelte-Ludwig, Carsten Terjung, Christoph Mahlert, Simone Greven, Anette Sommer, Sandra Berndt
  • Patent number: 11111312
    Abstract: The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the ?-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: September 7, 2021
    Assignee: ROCHE GLYCART AG
    Inventors: Oliver Ast, Peter Bruenker, Anne Freimoser-Grundschober, Sylvia Herter, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana
  • Patent number: 11091765
    Abstract: Methods and compositions are provided for oligonucleotides that bind targets of interest. The targets include cells and microvesicles, such as those derived from various diseases. The oligonucleotides can be used for diagnostic and therapeutic purposes. The target of the oligonucleotides can be a therapeutic target such as Complement Component 1, Q Subcomponent (C1q) or a subunit thereof.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: August 17, 2021
    Assignee: Caris Science, Inc.
    Inventors: Heather O'Neill, Mark Miglarese, David Spetzler
  • Patent number: 11077201
    Abstract: The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.
    Type: Grant
    Filed: January 3, 2020
    Date of Patent: August 3, 2021
    Assignee: Immunomedics, Inc.
    Inventors: Serengulam V. Govindan, Sung-Ju Moon, David M. Goldenberg
  • Patent number: 11065342
    Abstract: This invention relates to multi-specific molecules, such as long acting multi-specific antibodies. Also disclosed are relates methods.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: July 20, 2021
    Assignee: SHENZHEN ENDURING BIOTECH, LTD.
    Inventors: Shu-min Liu, Dechun Wu
  • Patent number: 11033607
    Abstract: Provided are GLP-1 C-terminal peptides and methods of use for the treatment or prevention of ischemic tissue injury. The peptides correspond to GLP-1(28-36). FIAWLVKGR and GLP-1(28-37) FIAWLVKGRG and are useful in the treatment or prevention of ischemic tissue injury, including ischemic heart disease or stroke.
    Type: Grant
    Filed: October 28, 2013
    Date of Patent: June 15, 2021
    Assignee: University Health Network
    Inventors: Mansoor Husain, Dhanwantee Mundil
  • Patent number: 11028375
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Grant
    Filed: March 3, 2020
    Date of Patent: June 8, 2021
    Assignee: ACCELERON PHARMA INC.
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • Patent number: 11020489
    Abstract: The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.
    Type: Grant
    Filed: April 6, 2020
    Date of Patent: June 1, 2021
    Assignee: Immunomedics, Inc.
    Inventors: Serengulam V. Govindan, Sung-Ju Moon, David M. Goldenberg
  • Patent number: 11001631
    Abstract: The present invention relates, in part, to agents that bind Clec9A and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the Clec9A binding agents and their use in the treatment of various diseases.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: May 11, 2021
    Assignees: Orionis Biosciences BV, VIB VZW, Universiteit Gent
    Inventors: Jan Tavernier, Nikolai Kley, Anje Cauwels, Sarah Gerlo
  • Patent number: 10974059
    Abstract: A method for the treatment of tumor(s) or tumor cell(s) or cancer(s) in a subject in need by the generation of heat. The latter is produced by chains of magnetosomes extracted from whole magnetotactic bacteria and subjected to an alternating magnetic field. These chains of magnetosomes yield efficient antitumoral activity whereas magnetosomes unbound from the chains or kept within the whole bacteria produce poor or no antitumoral activity. The introduction of various chemicals such as chelating agents and/or transition metals within the growth medium of the bacteria improves the heating properties of the chains of magnetosomes. Moreover, the insertion of the chains of magnetosomes within a lipid vesicle is also suggested in order to favor their rotation in vivo and hence to improve their heating capacity. The vesicle can contain an antitumoral agent together with the chains of magnetosomes. In this case, the agent is released within the tumors by heating the vesicle.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: April 13, 2021
    Assignee: NANOBACTERIE
    Inventors: Edouard Alphandery, Stephanie Faure, Imene Chebbi
  • Patent number: 10973923
    Abstract: The invention relates to site specific homogeneous binder drug conjugates of kinesin spindle protein inhibitors, to active metabolites of these conjugates, to processes for preparing these conjugates, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: April 13, 2021
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hans-Georg Lerchen, Yolanda Cancho Grande, Beatrix Stelte-Ludwig, Anette Sommer, Christoph Mahlert, Anne-Sophie Rebstock, Simone Greven, Nils Griebenow, Jan Tebbe, Oliver Kensch
  • Patent number: 10941208
    Abstract: Mucin 16 (MUC16) is highly expressed in ovarian cancer and expression on cancer cells is shown to protect tumor cells from the immune system. The present invention provides novel full-length human IgG antibodies that bind to human MUC16 (monospecific antibodies) and antigen-binding fragments thereof. In some embodiments, the anti-MUC16 antibodies and the antigen-binding fragments thereof are useful in diagnostic methods for identifying the presence of MUC16 in tissue and/or plasma samples.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: March 9, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lauric Haber, Eric Smith, Marcus Kelly, Jessica R. Kirshner, Sandra Coetzee, Alison Crawford, Thomas Nittoli, Yashu Liu
  • Patent number: 10941191
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: March 9, 2021
    Assignees: UNIVERSITY OF MARYLAND, BALTIMORE, GLIKNIK INC.
    Inventors: Scott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
  • Patent number: 10925971
    Abstract: Provided herein are methods of treating prolactin receptor positive breast cancer using an antibody drug conjugate (ADC) comprising an anti-PRLR antibody or antigen-binding fragment thereof conjugated to a cytotoxic agent. In certain embodiments, the anti-PRLR antibody or antigen-binding fragment thereof is conjugated to maytansinoid. In certain embodiments, the method of treating PRLR positive breast cancer includes administering the ADC in combination with one or more chemotherapeutic agents.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: February 23, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Marcus Kelly, Jessica Kirshner, Gavin Thurston
  • Patent number: 10918713
    Abstract: The invention relates to common allergen proteins and peptides, subsequences, portions, homologues, variants and derivatives thereof, and methods and uses of common allergen proteins and peptides. Methods include, for example, modulating an immune response; protecting a subject against or treating a subject for an allergic response, allergic disorder or allergic disease; and inducing immunological tolerance to the allergen in a subject.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: February 16, 2021
    Assignee: La Jolla Institute For Allergy And Immunology
    Inventors: Alessandro Sette, Carla Oseroff, Howard Grey, Bjoern Peters
  • Patent number: 10918736
    Abstract: The present invention relates to a conjugate in which an immunoglobulin Fc region is linked to therapeutic enzymes through a non-peptide polymer linkage moiety, and more specifically, to a conjugate in which a non-peptide polymer linkage moiety is specifically linked to an immunoglobulin Fc, a method of preparing the same, and a composition comprising the same.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: February 16, 2021
    Assignee: HANMI PHARM. CO., LTD
    Inventors: Dae Jin Kim, Jung Kuk Kim, Sung Youb Jung, Se Chang Kwon
  • Patent number: 10906990
    Abstract: The present invention relates to a monoclonal antibody or antibody fragment thereof as a human IgG antibody including at least one lysine derivative in a constant region of the human IgG antibody; a modified antibody or antibody fragment thereof, wherein the lysine derivative is modified; a nucleic acid including a nucleotide sequence encoding the antibody or antibody fragment thereof; a vector including the nucleic acid; a transformed cell obtained by introducing the vector into a host cell; a method for producing the antibody or antibody fragment thereof; and a composition containing the antibody or antibody fragment thereof.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: February 2, 2021
    Assignees: RIKEN, KYOWA KIRIN CO., LTD.
    Inventors: Kensaku Sakamoto, Kazumasa Ohtake, Yoshimi Yamaguchi, Shigeyuki Yokoyama, Tatsuo Yanagisawa, Akiko Matsumoto, Akifumi Kato, Yasuhisa Shiraishi, Kaname Kimura, Masakazu Homma
  • Patent number: 10870709
    Abstract: The present invention relates to antibodies and binding fragments thereof that bind the ?-sheet secondary structure of a pathological monomeric or oligomeric non-fibrillar proteins without binding to the non-toxic, non-pathological forms of these proteins or peptides These antibodies and binding fragments thereof are suitable for the diagnosis, prevention, and treatment of protein conformational disorders including all amyloid diseases.
    Type: Grant
    Filed: July 22, 2017
    Date of Patent: December 22, 2020
    Assignee: NEW YORK UNIVERSITY
    Inventors: Thomas M. Wisniewski, Fernando Goni
  • Patent number: 10835592
    Abstract: The present invention is directed to a bioconjugate vaccine, such as an O1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, D/E-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O1-bioconjugate in a bioreactor comprising a number steps.
    Type: Grant
    Filed: October 23, 2014
    Date of Patent: November 17, 2020
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Fabiana Fernandez, Michael Wetter, Michael Kowarik, Michael Wacker
  • Patent number: 10814036
    Abstract: Methods for the ex vivo modification of the surfaces of viable tissue result in tissue modifications that are stable and/or result in the controlled release of active compounds, and are expected to provide effective protection for transplanted tissue subsequent to transplant.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: October 27, 2020
    Assignee: BAYLOR UNIVERSITY
    Inventors: Bob Kane, Babatope Akinbobuyi, Charles Chang, Bashoo Naziruddin
  • Patent number: 10793626
    Abstract: Subject matter of the present invention is an anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold binding to the C-terminal portion of ADM, the aa 43-52 of ADM (SEQ ID NO: 1): APRSKISPQGY-NH2 for use in a therapy of cancer. Subject matter of the present invention is anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for use in the treatment of cancer according to claim 1 wherein said anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold requires the presence of a C-terminally amidated tyrosine residue within the C-terminal portion of ADM, the aa 43-52 of ADM (SEQ ID NO: 1): APRSKISPQGY-NH2, for binding.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: October 6, 2020
    Assignee: ANGIOBIOMED GMBH
    Inventor: Andreas Bergmann
  • Patent number: 10780294
    Abstract: A problem of incomplete inhibition of harmful cells/bacteria and short duration of time, after the photodynamic treatment, during which such cells may re-grow, is solved by exposing the target bacteria with a multi-component photosensitizer material formed by adding a predetermined potentiating chemical to a conventional single-component photosensitizer at the target, prior to irradiating the target with light. The multi-component photosensitizer is effectuated by forming a mix of the two chemical compositions or by sequential exposure of the bacteria to a single-component photosensitizer and the potentiating chemical of choice.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: September 22, 2020
    Assignee: The General Hospital Corporation
    Inventors: Daniela Vecchio, Michael R. Hamblin, Yingying Huang, Liyi Huang, Giacomo Landi, Jeffrey Gelfand, Timothy Brauns